Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: Avoiding withdrawal symptoms following antipsychotic discontinuation, reduction, or switch is an important factor when planning a safe and successful therapy. We performed a systematic review and meta-analysis concerning occurrence of withdrawal symptoms after discontinuation of antipsychotics. Data Sources: We searched the databases CENTRAL, Pubmed, and EMBASE with no restriction to the beginning of the searched time period and until October 1, 2019 (PROSPERO registration no. CRD42019119148). Study Selection: Of the 18 043 screened studies, controlled and cohort trials that assessed withdrawal symptoms after discontinuation of oral antipsychotics were included in the random-effects model. Studies that did not implement placebo substitution were excluded from analyses. The primary outcome was the proportion of individuals with withdrawal symptoms after antipsychotic discontinuation. We compared a control group with continued antipsychotic treatment in the assessment of odds ratio and number needed to harm (NNH). Data Extraction: We followed guidelines by the Cochrane Collaboration, PRISMA, and MOOSE. Results: 5 studies with a total of 261 individuals were included. The primary outcome, proportion of individuals with withdrawal symptoms after antipsychotic discontinuation, was 0.53 (95% CI, 0.37-0.70; I2 = 82.98%, P < 0.01). An odds ratio of 7.97 (95% CI, 2.39-26.58; I2 = 82.7%, P = 0.003) and NNH of 3 was calculated for the occurrence of withdrawal symptoms after antipsychotic discontinuation. Conclusion: Withdrawal symptoms appear to occur frequently after abrupt discontinuation of an oral antipsychotic. The lack of randomized controlled trials with low risk of bias on antipsychotic withdrawal symptoms highlights the need for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · cited 1×
“Furthermore, specific tapering strategies to reduce the risk of withdrawal symptoms were recently recommended for antidepressants: For example, Horowitz and Taylor (43) proposed a slow and hyperbolical taper strategy to mitigate SSRI withdrawal symptoms (43).”
BackgroundAntipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104 · cited 1×
“assessed individuals for seven days after discontinuation of clozapine 200 mg per day without placebo substitution and detected withdrawal symptoms in 61% of the 28 individuals (29).”
BackgroundDrug discontinuation effects are part of the pharmacology of a drug
Reidenberg, M. M. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183285 · Cited by 82
Nofzinger, E. A., van Kammen, D. P., Gilbertson, M. W., Gurklis, J. A., & Peters, J. L. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90024-8 · Cited by 61
Addiction theory matters—Why there is no dependence on caffeine or antidepressant medication
Heinz, A., Daedelow, L. S., Wackerhagen, C., & Di Chiara, G. (2020) · Addiction Biology · doi:10.1111/adb.12735 · Cited by 45 · cited 2×
“Individuals with antipsychotic withdrawal symptoms typically do not fulfil the addiction criteria as defined by the International Classification of Diseases (ICD-10 (11, 16).”
BackgroundSelf-citation
Cited by
Watson, N. F., Benca, R. M., Krystal, A. D., McCall, W. V., & Neubauer, D. N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072493 · Cited by 59
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06554-4 · Cited by 10
Metadata
- Authors
- Brandt, L., Bschor, T., Henssler, J., Müller, M., Hasan, A., Heinz, A., & Gutwinski, S.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2020-09-29
- Volume
- 11
- Pages
- 569912-569912
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3089427493
- Cited by
- 56
- References
- 9
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.